Study of Semaglutide Injections to Reduce Cannabis Use in Adults With Cannabis Use Disorder Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

What this Trial Is About

Researchers are evaluating whether the medicine semaglutide can help adults with cannabis use disorder reduce their cannabis use. This randomized, double-blind, placebo-controlled Phase 2 study will compare semaglutide to a placebo to see if it lowers cannabis consumption. The study also explores how brain activity changes in response to cannabis cues using functional brain scans in some participants. Participants will receive weekly injections of either semaglutide, titrated up to 2.4 mg, or a saline placebo for 20 weeks. The first 50 participants may have functional MRI scans at the start and end of treatment to observe brain responses. All participants will also take part in four supportive therapy sessions. After the 20-week treatment period, a follow-up visit will be conducted at week 46. During the study, cannabis use and other measures such as cannabis metabolites, craving, mood, sleep quality, alcohol and drug use severity, body weight, metabolic risk, and cardiovascular and glycemic parameters will be assessed at multiple time points. Blood and urine samples will be collected for safety and secondary outcomes. Researchers will monitor cannabis consumption as the primary outcome from baseline to week 20, with additional assessments continuing through the follow-up period.

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder